<DOC>
	<DOCNO>NCT00650910</DOCNO>
	<brief_summary>This two part study look effect lapatinib concentration digoxin blood drug dose together Part 1 ; look safety antitumor effect lapatinib use together possible additional anticancer therapy choose doctor 's discretion .</brief_summary>
	<brief_title>Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Metastatic , histologically confirm breast cancer overexpresses ErbB2 ( 3+ IHC , FISH , CISH positive ) . Is least 18 year age great 65 year age . Is male female . A female eligible enter participate study : Nonchildbearing potential ( i.e . physiologically incapable become pregnant ) , include female : Has hysterectomy Has bilateral oophorectomy ( ovariectomy ) Has bilateral tubal ligation , Is postmenopausal ( demonstration total cessation menses â‰¥ 1 year ) Childbearing potential , negative serum pregnancy test Screening agree one following : Doublebarrier contraception ( condom spermicidal jelly , foam , suppository , film ; diaphragm spermicide ; male condom diaphragm ) . Complete abstinence sexual intercourse two week prior administration study drug , throughout active study treatment period , Week 10 Visit . Vasectomized partner sterile prior female subject 's entry sole sexual partner female . Is able swallow retain oral medication . ECOG performance status 0 2 . Provided write informed consent . Adequate bone marrow function . Clinical lab result range state per protocol . Potassium magnesium within normal range institutional value . [ Serum potassium magnesium value fall outside normal range may repeat discretion investigator , provide consider clinically insignificant . ] Has leave ventricular ejection fraction ( LVEF ) within normal institutional range base ECHO MUGA . Life expectancy least 12 week Capable give write informed consent , include compliance requirement restriction list consent form . Is pregnant lactating . Has malabsorption syndrome , disease affect gastrointestinal function , resection stomach small bowel . Has evidence symptomatic uncontrolled brain metastasis leptomeningeal disease . Subjects brain metastasis treat surgery and/or radiotherapy eligible neurologically stable require steroid anticonvulsant . Is consider medically unfit study investigator result medical interview , physical exam , screen investigation . Has CTCAE Grade 2 great hypercalcemia per protocol . Has know immediate delay hypersensitivity reaction idiosyncrasy digoxin drug chemically relate investigational product gefitinib [ Iressa ] erlotinib [ Tarceva ] . Has receive treatment investigational drug previous four week . Has receive chemotherapy , immunotherapy , biologic therapy hormonal therapy treatment cancer within past 14 day , exception mitomycin C restrict past six week . Is currently receive amiodarone receive amiodarone six month prior screen . Is receive prohibit medication within timeframe indicate prohibited medication list per protocol . Has physiological , familial , sociological , geographical condition permit compliance protocol . Subjects certain disorder involve heart failure associate preserve left ventricular ejection fraction restrictive cardiomyopathy , constrictive pericarditis , amyloid heart disease , acute cor pulmonale , idiopathic hypertrophic subaortic stenosis , cardiac condition would preclude administration digoxin . Has clinically significant electrocardiogram ( ECG ) abnormality , include limited sinus node disease , preexist incomplete AV block , Wolff ParkinsonWhite Syndrome . Has inadequate venous access protocolrelated blood draw .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>lapatinib</keyword>
	<keyword>Metastatic ErbB2 positive breast cancer</keyword>
	<keyword>digoxin</keyword>
</DOC>